PMID: 17083573
Clinical Evidence for Extended-Interval GLP-1 Dosing Research published in endocrinology journals shows that patients tolerating standard weekly GLP-1 therapy often achieve comparable weight loss on extended schedules when doses are appropriately increased
Medi k8 C-Tetra , 39, 30ml
Daniel Drucker shares $3 million US prize with colleagues A Canadian researcher has won a 2025 Breakthrough Prize in Life Sciences for discovering the GLP-1 hormone used in diabetes and obesity medications including Ozempic, Wegovy and Mounjaro that have changed the lives of millions of people around the world
(Source: iPharma Pharmacy, 2026) A 2026 systematic review and meta-analysis (Prospero CRD42024535096) searched Cochrane Library, EMBASE, and Medline through September 2024, identifying 9,654 studies and including 11 randomized controlled trials comparing GLP-1 receptor agonists against no treatment, placebo, lifestyle intervention, oral contraceptives, anti-androgens, or metformin in PCOS patients
This is one of the most popular multi-additive formulations